Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher’s website for any subsequent corrections.

General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the Research Portal

Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling

Loïc Yengo1,2,3, Abdelillah Arredouani4, Michel Marre5,6,7, Ronan Roussel5,6,7, Martine Vaxillaire1,2,3, Mario Falchi5, Abdelali Haoudi9, Jean Tichet10, The D.E.S.I.R Study Group, Beverley Balkau11, Amélie Bonnefond1,2,3, Philippe Froguel1,2,3,8,

ABSTRACT

Objective: Characterizing specific metabolites in sub-clinical phases preceding the onset of type 2 diabetes to enable efficient preventive and personalized interventions.

Research design and methods: We developed predictive models of type 2 diabetes using two strategies. One strategy focused on the probability of incidence only and was based on logistic regression (MRS1); the other strategy accounted for the age at diagnosis of diabetes and was based on Cox regression (MRS2). We assessed 293 metabolites using non-targeted metabolomics in fasting plasma samples of 1,044 participants (including 231 incident cases over 9 years) used as training population; and fasting serum samples of 128 participants (64 incident cases versus 64 controls) used as validation population. We applied a LASSO-based variable selection aiming at maximizing the out-of-sample area under the receiver operating characteristic curve (AROC) and integrated AROC.

Results: Sixteen and 17 metabolites were selected for MRS1 and MRS2, respectively, with AROC = 90% and 73% in the training and validation populations, respectively. MRS2 had a similar performance and was significantly associated with a younger age of onset of type 2 diabetes (β = −3.44 years per MRS2 SD in the training population, $\rho = 1.56 \times 10^{-7}$; β = −4.73 years per MRS2 SD in the validation population, $\rho = 4.04 \times 10^{-3}$).

Conclusions: Overall, this study illustrates that metabolomics improves prediction of type 2 diabetes incidence of 4.5% on top of known clinical and biological markers, reaching 90% in total AROC, which is considered the threshold for clinical validity, suggesting it may be used in targeting interventions to prevent type 2 diabetes.

Keywords Type 2 diabetes; Metabolomics; Risk prediction; High dimensional regression; LASSO

1. INTRODUCTION

Characterizing metabolic disruptions preceding the onset of type 2 diabetes is critical to identify individuals at risk, especially at the early asymptomatic stages of the disease when intervention can be most effective. Given the high rate of complications associated with long duration hyperglycemia [1], it is particularly important to prevent or at least delay type 2 diabetes in individuals in their early forties or younger. Although epidemiological studies have reported numerous risk factors for type 2 diabetes [2,3], the predictive performances of statistical models based on these predictors still need to be improved. Different approaches such as genome-wide association studies (GWAS) have been proposed to identify new risk factors. GWAS have generated a catalog of replicated genetic loci that includes up to 100 variants [4]. However, these genetic variants only explain an unexpectedly small fraction (<15%) of type 2 diabetes estimated heritability and their inclusion only marginally improves the performances of previously existing predictive models [5,6].

Metabolomics, defined as the comprehensive analysis of low-molecular weight metabolites produced by a system, has recently emerged for disease diagnosis and biomarker identification [7]. Several studies showed that high levels of the branched-chain amino acids (BCAA) such as leucine, isoleucine, and valine as well as high levels of the aromatic amino acids phenylalanine and tyrosine are strong predictors of insulin resistance and type 2 diabetes [8–11]. Furthermore, increased plasma levels of alpha-hydroxybutyrate (AHB)
and decreased levels of 1-linoleyl-glycerophosphocholine (L-GPC) were associated with glucose intolerance [12]. Other studies also have reported carbohydrates (glucose, mannose, 1,5-anhydroglucitol [13,14], gamma-glutamyl derivatives (γ-glutamylphenylalanine, γ-glutamyltyrosine, γ-glutamylvaline) [15], glycine [14], and serine [19] as good predictors of type 2 diabetes.

Despite this increasing catalog of potential predictors, statistical approaches implemented to train predictive models suffer from two main limitations. The first limitation relates to the commonly admitted assumption that significantly associated (often under a regression framework) metabolites would automatically be good predictors [16]. Although partially true, this assumption ignores that predictive performances are driven not only by a significant shift in the metabolite mean level (as classically captured by a test of association) but also generally by any change in the entire distribution of the metabolites. As a consequence, if the variance of a metabolite is significantly different between incident cases and controls, despite no significant difference in means, the latter metabolite can be a rather good predictor.

The second limitation of most implemented approaches is that the bivalent notion of incidence is often overlooked. Indeed, incidence covers two distinct, yet complementary, aspects that are: first, the probability of developing the disease in the future, and secondly the speed at which this occurs (Supplementary Figure 1). Most studies using metabolomics to study the incidence of type 2 diabetes have been focused only on characterizing the probability to develop the disease, but have mostly ignored the second aspect of incidence. This is illustrated by the recurrent use of logistic regression models in the related literature [6,8,10,12,14,17]. Even when more suitable models such as Cox regression are used, the model performances are often assessed using static metrics such as the area under the receiver operating characteristic curve (AROC) or the net reclassification index (NRI). Instead, the use of dynamic metrics such as the integrated time-dependent AROC (iAROC) should be used to take full advantage of the time-dependent nature of the predicted outcome [18]. One expected consequence of these classical modeling choices is a sub-optimal performance in both evaluating the probability of the incidence and predicting who will develop the disease earlier or later.

The present study aimed to overcome these two limitations by calibrating two predictive models; one focused on the probability to develop type 2 diabetes in the future regardless of the time scale (Strategy 1: Metabolomic Risk Score 1; MRS1) and the other trying to simultaneously predict the risk and the age of onset (Strategy 2: Metabolomic Risk Score 2; MRS2). To complete this aim, we used a comprehensive profiling of metabolites in plasma and serum samples from middle-aged participants of prospective cohorts. The comparison of the two prediction strategies is an underlying aim of this study that would bring to light metabolites simultaneously and/or specifically contributing to type 2 risk and early onset of diabetes. We also aimed to evaluate the stability over time of the metabolites found through both strategies, which is a key element in their clinical use. Indeed, targeting metabolites conserved in time is mandatory to implement any measurable preventive intervention. Finally, we aimed to investigate the capacity of the calibrated predictive models to improve risk prediction on top of known clinical and biological risk factors.

2. RESEARCH DESIGN AND METHODS

2.1. Training population

We studied men and women who participated in the nine-year follow-up study D.E.S.I.R., a middle-aged, European cohort [5,19,20]. A case-cohort design was used to include 231 cases of incident type 2 diabetes and 836 participants randomly sampled from the entire cohort. Baseline and follow-up clinical characteristics of participants included in the training population are shown in Supplementary Table 1. Type 2 diabetes was defined using one of the following criteria: use of glucose lowering medication, fasting plasma glucose [FG] ≥7 mmol/L, or glycated hemoglobin A1c [HbA1c] ≥6.5% (48 mmol/mol) [21]. Clinical and biological evaluations were performed at inclusion and after three, six, and nine years, as previously described [22,23]. All participants provided written informed consent and the study protocol was approved by the Ethics Committee for the Protection of Subjects for Biomedical Research of Bicêtre Hospital, France.

2.2. Validation population

To provide an external assessment of the predictive models from the training population, we selected 64 incident type 2 diabetes cases and 64 controls (matched on age at inclusion, sex and body mass index [BMI]) from French families with type 2 diabetes or obesity recruited by the CNRS UMR8199 unit (Lille, France) [24–26]. Among the recruited participants we selected those with baseline characteristics (age, sex, BMI, fasting glucose, 2-hour glucose and glucose lowering treatment) available, with a follow-up including at least two measurements and with at least 100 µL of fasting serum available. Baseline clinical characteristics of participants included in the validation population are shown in Supplementary Table 1. Type 2 diabetes was defined using the following criteria: use of glucose lowering medication, fasting plasma glucose [FG] ≥7 mmol/L, or 2-hour glucose ≥ 11 mmol/L. The average follow-up length was 8.6 years (standard deviation: 4.6 years) in the validation population. Informed consent was obtained from all subjects, and the study was approved by the ethics committees from Lille, France.

2.3. Metabolite measurements

Metabolomic measurements were performed in fasting plasma samples from D.E.S.I.R. participants and in fasting serum samples from those included in the validation population. All fasting plasma and serum samples were processed by the Metabolon (Durham, NC) platform using GC/MS and LC/MS/MS as previously described [27,28]. Since the analysis spanned a number of days, a data normalization step was applied to correct inter-day variations. Each compound was identified using a standard external calibration and each data point was normalized. We analyzed 293 metabolites (intersection between 491 detected in plasma and 625 detected in serum) that were detected (missing value rate <20%) in both plasma and serum samples. Metabolites were divided into two categories according to their missing value rate. The first category involved 255 metabolites with missing value rate <5% in either plasma or serum samples. For these metabolites, missing values were imputed with the smallest detected value. The second category involved 38 metabolites, for which the missing value rate ranged from 5% to 80%. These metabolites were analyzed as binary exposures (presence vs absence) and observed values were coded “1” and missing values “0”.

2.4. Clinical and biological risk factors

We used several clinical and biological type 2 diabetes risk factors to compare the discriminative performances of metabolomic markers with established predictors. We restricted the set of clinical and biological risk factors assessed in this study to risk factors available in both training and validation populations. Listed below, the latter risk factors were dichotomized so as to define a stratum at higher risk vs a
Metabolites contributing to MRS1 and MRS2. The first nine metabolites contribute to both scores and the 15 others are specific to each score. Relative contributions $\geq 1/16 = 6.25\%$ for MRS1 and $\geq 1/17 = 5.88\%$ for MRS2 are highlighted in bold font. Relative contribution ratios for the two scores that are above 2 are also highlighted in bold font. References are given for metabolites reported in the literature for associations with insulin resistance or prevalent and incident type 2 diabetes.

<table>
<thead>
<tr>
<th>Metabolites</th>
<th>Associated pathways</th>
<th>MRS1</th>
<th>Regression coefficient</th>
<th>Relative contribution to the score</th>
<th>MRS2</th>
<th>Regression coefficient</th>
<th>Relative contribution to the score</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,5-Anhydroglucitol</td>
<td>Glycolysis, gluconeogenesis, Pynvuate</td>
<td>0.50</td>
<td>9.77%</td>
<td>-0.26</td>
<td>7.13%</td>
<td>-0.25</td>
<td>6.96%</td>
<td>[13,14]</td>
</tr>
<tr>
<td>1-Linoleoyl-GPC</td>
<td>Lysolipid</td>
<td>-0.31</td>
<td>5.97%</td>
<td>-0.07</td>
<td>1.92%</td>
<td>-0.03</td>
<td>1.89%</td>
<td>[12]</td>
</tr>
<tr>
<td>1-Palmitylglycerol</td>
<td>Monoacylglycerol</td>
<td>0.16</td>
<td>3.10%</td>
<td>0.25</td>
<td>6.96%</td>
<td>0.09</td>
<td>2.61%</td>
<td>[29]</td>
</tr>
<tr>
<td>Cotinine</td>
<td>Tobacco Metabolite</td>
<td>0.33</td>
<td>6.34%</td>
<td>0.32</td>
<td>8.68%</td>
<td>0.32</td>
<td>2.61%</td>
<td>[3]</td>
</tr>
<tr>
<td>$\gamma$-Glutamylphenylalanine</td>
<td>Gamma-glutamyl Amino Acid</td>
<td>0.17</td>
<td>3.34%</td>
<td>0.09</td>
<td>2.61%</td>
<td>0.09</td>
<td>2.61%</td>
<td>[15]</td>
</tr>
<tr>
<td>Glucose</td>
<td>Glycolysis, gluconeogenesis, Pynvuate</td>
<td>0.10</td>
<td>2.00%</td>
<td>0.51</td>
<td>13.8%</td>
<td>0.51</td>
<td>13.8%</td>
<td>[13,14]</td>
</tr>
<tr>
<td>Isoleucine</td>
<td>Leucine, Isoleucine, Valine</td>
<td>0.28</td>
<td>5.39%</td>
<td>0.27</td>
<td>7.33%</td>
<td>0.27</td>
<td>7.33%</td>
<td>[13,14]</td>
</tr>
<tr>
<td>Mannose</td>
<td>Fructose, Mannose, Galactose</td>
<td>0.37</td>
<td>7.26%</td>
<td>0.13</td>
<td>3.48%</td>
<td>0.13</td>
<td>3.48%</td>
<td>[13,14]</td>
</tr>
<tr>
<td>Pro-hydroxy-pro</td>
<td>Urea cycle, Arginine, Proline</td>
<td>-0.30</td>
<td>5.85%</td>
<td>-0.16</td>
<td>4.0%</td>
<td>-0.16</td>
<td>4.0%</td>
<td>[13,14]</td>
</tr>
<tr>
<td>Fructose</td>
<td>Fructose, Mannose, Galactose</td>
<td>0.27</td>
<td>5.21%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\gamma$-Glutamyltyrosine</td>
<td>Gamma-glutamyl Amino Acid</td>
<td>0.29</td>
<td>5.59%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[15]</td>
</tr>
<tr>
<td>Isovalerylcarnine</td>
<td>Leucine, Isoleucine, Valine</td>
<td>0.19</td>
<td>3.73%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[15]</td>
</tr>
<tr>
<td>Phenylalanine</td>
<td>Phenylalanine, Tyrosine Metabolism</td>
<td>0.28</td>
<td>5.48%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[10,13]</td>
</tr>
<tr>
<td>Piperine</td>
<td>Food Component/Plant</td>
<td>0.30</td>
<td>5.91%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serine</td>
<td>Glycine, Serine, Threonine</td>
<td>-0.31</td>
<td>6.08%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[15]</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>Phenylalanine, Tyrosine Metabolism</td>
<td>-0.05</td>
<td>0.97%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[10]</td>
</tr>
<tr>
<td>1-Stearyloyl-GPI</td>
<td>Lysolipid</td>
<td>-0.26</td>
<td>7.11%</td>
<td>4.03%</td>
<td></td>
<td></td>
<td></td>
<td>[13]</td>
</tr>
<tr>
<td>3-Hydroxyisobutyrate</td>
<td>Leucine, Isoleucine, Valine</td>
<td>0.15</td>
<td>4.03%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[13]</td>
</tr>
<tr>
<td>Dehydroisandrosterone sulfate</td>
<td>Steroid</td>
<td>0.30</td>
<td>8.27%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[13]</td>
</tr>
<tr>
<td>$\gamma$-Glutamylvaline</td>
<td>Gamma-glutamyl Amino Acid</td>
<td>0.12</td>
<td>3.39%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[15]</td>
</tr>
<tr>
<td>Glycine</td>
<td>Glycine, Serine, Threonine</td>
<td>-0.13</td>
<td>3.45%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[10,17]</td>
</tr>
<tr>
<td>Palmitoyl sphingomyelin</td>
<td>Sphingolipid Metabolism</td>
<td>-0.14</td>
<td>3.93%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[14]</td>
</tr>
<tr>
<td>Stearoylcarnine</td>
<td>Fatty Acid Metabolism (Acyl Carnitine)</td>
<td>-0.19</td>
<td>5.12%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[14,15]</td>
</tr>
<tr>
<td>Urea</td>
<td>Urea cycle, Arginine, Proline</td>
<td>-0.31</td>
<td>8.40%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>[14,15]</td>
</tr>
</tbody>
</table>

Stratum at lower risk: sex (men vs women), age (≥45 vs <45 years), body mass index (BMI: ≥25 vs <25 kg/m²), fasting glucose (FG ≥5.6 vs <5.6 mmol/L), blood pressure (BP: diagnosed hypertension or systolic BP ≥130 or diastolic BP > 85 mm Hg vs no hypertension and systolic BP <130 and diastolic BP < 85 mm Hg), triglycerides (TG: TG ≥1.7 vs <1.7 mmol/L), high density lipoprotein (HDL) cholesterol (<1.03 in men or <1.29 mmol/L in women vs >1.03 in men and >1.29 mmol/L in women), smoking status (current smoker vs current non-smoker), waist circumference (WC: WC ≥94 in men and ≥80 cm in women vs <94 in men and <80 cm in women). The thresholds used to dichotomize continuous risk factors were chosen from the harmonized definition of the metabolic syndrome [29].

2.5 Statistical analyses

The characteristics of participants are described by mean (SD) and n (%) in Supplementary Table 1. Two strategies for predicting incident type 2 diabetes were implemented. The first one relies on multivariable logistic regression only modeling the probability of developing type 2 diabetes, while the second, based on multivariable Cox regression with age as the time scale, tries to simultaneously identify those with an early age at diagnosis. These two models used 293 metabolites as explanatory variables and the Least Absolute Shrinkage and Selection Operator (LASSO) regularization was applied [30] to select the most relevant metabolites. We used 3-fold cross-validation to select the number of metabolites to include in the logistic regression (strategy 1) and Cox regression (strategy 2) models. The number of metabolites in each model was selected to maximize the averaged AROC for logistic regression, and the averaged integrated AROC [18] (iAROC) for Cox regression, over 10,000 replications (Supplementary Figures 2 and 3). For any given number of metabolites, 95% confidence intervals for averaged AROC and iAROC were calculated as the intervals centered on the averaged values and containing 95% of the generated AROC values over the 10,000 replications. All models were fitted using two thirds of the training population only.

To assess the stability of metabolites between baseline and year nine, we compared the average values between these two time points using paired t-tests as well as the correlation between these two measurements. This comparison was performed for each of the identified metabolites in the 778 D.E.S.I.R participants included in the random sample cohort and who remained non-diabetic during the
Using 3-fold cross-validation in D.E.S.I.R. samples, we found that 17 metabolites could discriminate incident cases from controls while simultaneously accounting for the age of onset (Table 1). Including more metabolites led to over-fitting and, consequently, to reduced out-of-sample discriminative performances (Supplementary Figure 3). Among these 17 metabolites we found six lipids (L-GPC, 1-palmitoylglycerol, 1-steinol-GPI, dehydroxyostranol, sulfat (DHEA-S), palmitoyl spingomyel, and stearoylcarnitine), five BCAA derivatives (3-hydroxyisobutyrate, glycine, isoleucine, pro-hydroxypro, and urea), three carbohydrates (mannose, glucose, and 1,5-anhydroglucitol), one peptide (γ-glutamyphenylalanine), and one xenobiotic (cotinine) (Table 1).

3.2. Strategy 2: Predicting the incidence of type 2 diabetes accounting for the age at diagnosis

Using 3-fold cross-validation in D.E.S.I.R samples, we found that 17 metabolites could discriminate incident cases from controls while simultaneously accounting for the age of onset (Table 1). Including more metabolites led to over-fitting and, consequently, to reduced out-of-sample discriminative performances (Supplementary Figure 3). Among these 17 metabolites we found six lipids (L-GPC, 1-palmitoylglycerol, 1-steinol-GPI, dehydroxyostranol, sulfat (DHEA-S), palmitoyl spingomyel, and stearoylcarnitine), five BCAA derivatives (3-hydroxyisobutyrate, glycine, isoleucine, pro-hydroxypro, and urea), three carbohydrates (mannose, glucose, and 1,5-anhydroglucitol), one peptide (γ-glutamyphenylalanine), and one xenobiotic (cotinine) (Table 1).

3.3. Comparison of MRS1 and MRS2

Strategies 1 and 2 led to different sets of metabolites to be included in MRS1 and MRS2. Nonetheless, nine metabolites were common to both strategies: 1,5-anhydroglucitol, L-GPC, 1-palmitoylglycerol, cotinine, γ-glutamyphenylalanine, glucose, isoleucine, mannose and pro-hydroxy-pro (Table 1). The regression coefficients associated with these metabolites were sign consistent in each risk score (Table 1).
Similarly, mannose had 2.1-times more weight in MRS1 than in MRS2 (3.1-fold larger in MRS1. Indeed, the contribution of 1-palmitoylglycerol was 2.2-fold larger in MRS1 and MRS2. The ROC curves for all models are shown in Figure 1.

To assess the relative predictive performances of MRS1 and MRS2 in comparison with classic clinical and biological risk factors, we considered three predictive models: Model 1 included all clinical and biological risk factors listed in the Clinical and biological risk factors section; Model 2 included only MRS1 when the metrics used for comparison is AROC; or only MRS2 when the metrics used for comparison is iAROC; and Model 3 included all predictors in Model 1 plus MRS1 or MRS2. The ROC curves for all models are shown in Figure 1. In D.E.S.I.R. participants, Model 1 yielded an AROC and an iAROC of 83.7% and 60.5%, respectively. In the validation population, however, the performances of these models were lower: AROC = 86.5% vs iAROC = 52.5% (Table 3). Finally, the most comprehensive model, namely Model 3, had significantly better predictive performances than Model 1 in D.E.S.I.R. participants, both in terms of AROC and iAROC (p < 5.97 × 10⁻³, Table 3). In the validation population, however, only MRS2 yielded a statistically better iAROC than Model 1 (+15.4%; p = 9 × 10⁻³, Table 3).
performances than Model 1 and Model 2 in D.E.S.I.R. participants (largest AROC = 89.8%; \( p < 5 \times 10^{-3} \); Table 3) but was less predictive than Model 2 in the validation population.

3.5. Time conservation of identified metabolites

We assessed the time conservation of the 24 metabolites (16 in MRS1, 17 in MRS2 but 9 in common) involved in MRS1 and/or MRS2 by comparing baseline to follow-up (nine years after) levels as well as by estimating correlation coefficients between these two measurements in D.E.S.I.R. participants. We found that correlations between baseline and follow-up were strongly significant (\( p < 5 \times 10^{-7} \); Supplementary Table 3) for all metabolites, except for 1-steinol-GP (\( r = 0.08, p = 0.02 \); Supplementary Table 3) and fructose (\( r = 0.05, p = 0.15 \); Supplementary Table 3). However, we observed that 12 metabolites significantly increased and seven decreased with age during the nine years follow up (\( p < 0.05 \); Supplementary Table 3). Two metabolites, 1,5-AG and DHEA-S, were particularly well conserved, as their between-measurements correlation was above 0.73 (\( p < 10^{-16} \)) which is larger than HbA1c (\( r = 0.63 [0.58–0.67]_{95\% CI} \) data not shown). Among the metabolites analyzed as binary predictors (detected vs not-detected), we found that cotinine, piperine and stearylarnitine were the most stable with a concordance of >79% (data not shown) between baseline and follow-up measurements.

4. CONCLUSIONS

This study proposes two strategies for predicting incident type 2 diabetes. The first one relies on multivariable logistic regression, modeling only the probability of developing type 2 diabetes, while the second, based on multivariable Cox regression, tries also to identify those with an early age at diagnosis. The performances of these two strategies were assessed using both out-of-sample cross validation and an actual validation sample, which emphasizes their applicability to external populations.

This study also illustrates the complementarity of these two approaches especially since identifying early type 2 diabetes converters has a major impact on their overall mortality risk as previously reported [31]. We found that some metabolites only contributed to one model, and for those shared by the two models, their relative contributions could vary. Indeed, metabolites involved in steroid, lysolipid, and fatty acid metabolism were specifically identified when the age at diagnosis was accounted for in the Cox model. Moreover, when focusing on metabolites selected in both models, we observed that relative weights of lipids (1-palmitoiglycerol and L-GPC) differed between the two scores. This underlines the important role of lipid metabolism in accelerating the onset of type 2 diabetes.

The complementarity between those two modeling strategies was emphasized by the comparison of MRS1 and MRS2 with clinical and biological predicting risk factors. Our study strongly confirms that metabolomic markers have a significant added-value on top of classic type 2 diabetes predictors (including glucose) as previously reported [6]. Importantly, in our study, the improvement in the AROC brought by metabolomics is larger (+4.5%) than previously reported [6] with an AROC close to 90% when metabolomic, biological, and clinical factors are used together. This illustrates that such a combined score could be clinically valid to discriminate those who will and will not become diabetic. In contrast, for the second modeling strategy taking into analysis the age at diagnosis, the discriminative power of MRS2 alone was better than when combined with classic predictors.

Our data may be useful to better design preventive intervention by stratifying and further targeting individuals with both large MRS1 and MRS2 scores as illustrated in Supplementary Figure 4. We observed that the discriminative performances of MRS1 and MRS2 were lower in the validation sample than in the training sample. Given that a reduction in discriminative performances was similarly observed when using clinical and biological risk factors only, we assume that the reduced performances of MRS1 and MRS2 are not due to over-fitting. Instead, the reduced performances of MRS1 and MRS2 in the validation population can be explained by marked differences regarding clinical parameters between the two populations. Indeed, participants in the validation population all had a family history of type 2 diabetes and/or obesity and were themselves mostly obese (Supplementary Table 1). Despite their reduced performances, MRS1 and MRS2 remained more predictive than known risk factors (Table 3) in this population already at high risk for type 2 diabetes. Although MRS1 and MRS2 also improve the specificity of type 2 diabetes prediction here, other risk factors, possibly rare family shared mutations or other metabolites not detected, remain to be identified.

We showed that MRS2 was simultaneously more predictive in younger individuals and in those with very mild impaired fasting glucose (defined by fasting glucose at baseline higher than 5.6 mmol/L which is far lower than the alternative definition of prediabetes — 6.1 mmol/L). This important finding reinforces the relevance of aiming for early preventive intervention. Indeed, as previously pointed out in the Whitehall II study [32], future incident diabetes cases often present fasting glucose above 5.6 mmol/L up to 10 years before the onset of type 2 diabetes. At that time the identification of people at risk of diabetes and preventive intervention are the most useful to prevent diabetes onset.

In contrast to genetic studies, the number and nature of the metabolites accurately measured by the different available technical platforms and the reproducibility of the metabolomic data from these
platforms is still an unresolved issue. Despite that limitation, the vast majority of the 24 metabolites highlighted in this paper had previously been shown to be associated with type 2 diabetes or with insulin resistance [10,12–15,17,33] (Table 1). We are therefore confident that they are truly predictive of diabetes.

One strength of our study was the analysis of the conservation over time of the 24 identified type 2 diabetes metabolites. The most stable metabolites were 1,5-AG and DHEA-S. Stability over shorter spans of time (1 and 7 years) of 1,5-AG and DHEA-S was previously reported in the study by Yousri et al. (2014) [34]. The latter study also reported a relatively good time conservation (0.4 < r < 0.5) of glycine, isoleucine, isovalerylcarnitine and γ-glutamylvaline, 1,5-AG, DHEA-S glycine, isoleucine, isovalerylcarnitine and γ-glutamylvaline. Furthermore, 1,5-AG levels in saliva were associated with type 2 diabetes risk [35]. In addition, we also reported the stability of two xenobiotics, cotinine (tobacco consumption) and piperine (pepper consumption), which suggests the stability of the environment contributing to diabetes onset. Finally, we confirmed that urea and serine, previously reported for their association with chronological age [36], significantly varied with age during the 9 year follow-up. Altogether, our data suggest that these stable biomarkers can be safely used for large scale type 2 diabetes risk prediction.

In conclusion, the present study highlights that few biomarkers with an efficient combination as risk scores can improve the identification of incident type 2 diabetes cases, especially in those poorly recognized by classical clinical risk factors. The clinical use of such biomarkers are important for the development of early interventions for the prevention of type 2 diabetes, involving changes in life style and pharmacotherapy. A comprehensive list of metabolomic biomarkers, as well as an assessment of their predictive capacity, is under construction through a number of research studies. Our study contributes to this effort. However, to complement our findings, additional research is needed to understand the potential causality relating metabolomic biomarkers and other known risk factors to the onset of type 2 diabetes. For this, the use of statistical methodologies such as mediation analyses [37,38] and Mendelian randomization [39] could provide avenues for further improvement.

CONTRIBUTION STATEMENT

MF, BB and PF designed the study. LY performed data acquisition, data analysis, drafted and wrote the manuscript. LY, AA, AB and PF interpreted the data. AB and PF contributed to writing the manuscript. AA, MM, RR, MV, AH and BB reviewed the manuscript. All authors have read and approved the final version of the manuscript.

ACKNOWLEDGMENTS

We are grateful to all participants of this study. The D.E.S.I.R. Study Group is composed of Inserm-U1018 (Paris: B. Balkau, P. Ducimetière, E. Eschwège), Inserm-U0367 (Paris: F. Anthec-Gelas), CHU d’Angers (A. Girault), Bichat Hospital (Paris: F. Fumeron, M. Marre, R. Rousssel): CHU de Reims (F. Bonnet), CNRS UMR-8199 (Lille: S. Cauchi, P. Frougeau), Medical Examination Services (Alençon, Angers, Blois, Caen, Chartres, Châteauroux, Cholet, Le Mans, Orléans and Tours), Research Institute for General Medicine (J. Cogneau), General practitioners of the region, and Cross-Regional Institute for Health (C. Born, E. Caces, M. Cailleau, N. Copin, O. Lantieri, J.G. Moreau, F. Rakotozafy, J. Tichet, S. Vol).

This study was supported by Qatar Foundation and the Centre National de la Recherche Scientifique (CNRS). The D.E.S.I.R. study has been supported by Inserm contracts with CNAMTS, Lilly, Novartis Pharma and Sanofi-aventis, and by Inserm (Réseaux en Santé Publique, Interactions entre les déterminants de la santé, Cohortes Santé TGR 2008), the Association Diabète Risque Vasculaire, the Fédération Française de Cardiologie, La Fondation de France, ALFEDIAM. ONIVANS, Société Francophone du Diabète, Antix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche and Topcon.

CONFLICTS OF INTEREST

None declared.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.molmet.2016.08.011.

REFERENCES


Original Article


[38] InterAct Consortium, et al., 2013. The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study. Diabetes 56(1):60–69.